ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer
Overall survival results from a study with a combination of [...]
ASCO GU 2020: New drug, sitravatinib in combination with nivolumab for second-line treatment of advanced kidney cancer
The results from one of the first clinical trials of [...]
ASCO GU 2020: Adding radiotherapy to immunotherapy for the treatment of metastatic kidney cancer
Two clinical trials looking at the use of radiotherapy and [...]
ASCO GU 2020: Randomised clinical trial of HIF-2α inhibitor in patients with advanced kidney cancer
A randomised clinical trial of hypoxia inducible factor 2α (HIF-2α) [...]
ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
Ilixadencel improves responses and survival in metastatic kidney cancer
Results from a recent phase 2 clinical trial of ilixadencel [...]
Flu vaccine could one day be used to treat cancer
An early study in mice, published in Proceedings of the National [...]
Integrative oncology: using evidence-based medicine to improve patient outcomes and quality of life
A recent article published in Cancer Therapy Advisor describes what [...]
ABPI Patient Organisation Forum: Patient centricity
KCSN is a member of the Association of the British [...]
First-line treatment of papillary renal cell carcinoma with sunitinib
Papillary renal cell carcinoma (PRCC) is a rare subtype of [...]
